Zoetis Inc. (NYSE:ZTS) Shares Sold by Princeton Capital Management LLC

Princeton Capital Management LLC reduced its stake in shares of Zoetis Inc. (NYSE:ZTS - Free Report) by 61.3% during the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 3,852 shares of the company's stock after selling 6,110 shares during the quarter. Princeton Capital Management LLC's holdings in Zoetis were worth $634,000 as of its most recent SEC filing.

Several other large investors also recently added to or reduced their stakes in ZTS. Navigoe LLC bought a new stake in Zoetis during the fourth quarter worth approximately $30,000. Cornerstone Planning Group LLC increased its stake in Zoetis by 79.3% during the first quarter. Cornerstone Planning Group LLC now owns 199 shares of the company's stock worth $30,000 after acquiring an additional 88 shares during the last quarter. Migdal Insurance & Financial Holdings Ltd. increased its stake in Zoetis by 87.6% during the first quarter. Migdal Insurance & Financial Holdings Ltd. now owns 257 shares of the company's stock worth $42,000 after acquiring an additional 120 shares during the last quarter. Murphy & Mullick Capital Management Corp bought a new position in shares of Zoetis during the fourth quarter valued at approximately $44,000. Finally, Sound Income Strategies LLC grew its stake in shares of Zoetis by 141.4% during the first quarter. Sound Income Strategies LLC now owns 280 shares of the company's stock valued at $46,000 after buying an additional 164 shares during the last quarter. 92.80% of the stock is owned by institutional investors.

Insiders Place Their Bets

In other Zoetis news, EVP Roxanne Lagano sold 652 shares of the company's stock in a transaction on Tuesday, June 3rd. The stock was sold at an average price of $170.00, for a total transaction of $110,840.00. Following the completion of the sale, the executive vice president owned 15,129 shares in the company, valued at $2,571,930. This represents a 4.13% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. 0.16% of the stock is currently owned by corporate insiders.

Analyst Upgrades and Downgrades

A number of research analysts have recently commented on ZTS shares. UBS Group cut their target price on Zoetis from $189.00 to $170.00 and set a "neutral" rating on the stock in a research note on Wednesday, May 7th. Stifel Nicolaus cut Zoetis from a "buy" rating to a "hold" rating and cut their target price for the company from $165.00 to $160.00 in a research note on Wednesday, June 18th. Leerink Partners cut Zoetis from an "outperform" rating to a "market perform" rating and cut their target price for the company from $180.00 to $155.00 in a research note on Thursday, July 17th. Leerink Partnrs cut Zoetis from a "strong-buy" rating to a "hold" rating in a research note on Thursday, July 17th. Finally, Piper Sandler upped their target price on Zoetis from $205.00 to $210.00 and gave the company an "overweight" rating in a research note on Monday, May 12th. Four analysts have rated the stock with a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and a consensus price target of $204.63.

Zoetis Trading Down 0.1%

Shares of NYSE ZTS traded down $0.19 during trading hours on Monday, reaching $151.93. The stock had a trading volume of 816,257 shares, compared to its average volume of 3,035,711. The business's fifty day moving average price is $159.91 and its two-hundred day moving average price is $160.96. The company has a current ratio of 1.74, a quick ratio of 1.04 and a debt-to-equity ratio of 1.12. The firm has a market cap of $67.64 billion, a price-to-earnings ratio of 27.28, a P/E/G ratio of 2.52 and a beta of 0.91. Zoetis Inc. has a 52-week low of $139.70 and a 52-week high of $200.33.

Zoetis (NYSE:ZTS - Get Free Report) last posted its earnings results on Tuesday, May 6th. The company reported $1.48 earnings per share for the quarter, topping analysts' consensus estimates of $1.40 by $0.08. The company had revenue of $2.22 billion during the quarter, compared to analyst estimates of $2.20 billion. Zoetis had a return on equity of 55.48% and a net margin of 27.12%. Zoetis's revenue was up 1.4% on a year-over-year basis. During the same quarter in the prior year, the business earned $1.38 earnings per share. Analysts expect that Zoetis Inc. will post 6.07 EPS for the current fiscal year.

Zoetis Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Wednesday, September 3rd. Shareholders of record on Friday, July 18th will be issued a dividend of $0.50 per share. The ex-dividend date of this dividend is Friday, July 18th. This represents a $2.00 dividend on an annualized basis and a yield of 1.32%. Zoetis's dividend payout ratio is currently 35.91%.

About Zoetis

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.